Peter Blume-Jensen - 21 Nov 2024 Form 4 Insider Report for Acrivon Therapeutics, Inc. (ACRV)

Role
President and CEO, Director
Signature
/s/ Rasmus Holm-Jorgensen, Attorney-in-Fact for Peter Blume-Jensen
Issuer symbol
ACRV
Transactions as of
21 Nov 2024
Net transactions value
-$128,220
Form type
4
Filing time
25 Nov 2024, 16:29:31 UTC
Previous filing
18 Nov 2024
Next filing
19 Feb 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACRV Common Stock Tax liability $128,220 -19,910 -0.84% $6.44 2,342,837 21 Nov 2024 Direct F1, F2
holding ACRV Common Stock 316,756 21 Nov 2024 See Footnote F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.
F2 These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein.
F3 These securities are held by co-founder and EVP, Dr. Kristina Masson, who is also Dr. Blume-Jensen's spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.